Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

ProEthic starts PRO-513 Phase III

May 23, 2006 12:25 AM UTC

ProEthic (Montgomery, Ala.) started the double-blind, placebo-controlled Phase III IMPACT trial of PRO-513 to treat migraine headaches. The co-primary endpoints of the North American trial in 650 pati...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article